[{"id":"86f5d623-e383-4b3e-8efb-11c16dbf36fa","acronym":"Catalyst","url":"https://clinicaltrials.gov/study/NCT05383170","created_at":"2023-02-21T18:01:52.866Z","updated_at":"2025-02-25T16:17:43.709Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers","source_id_and_acronym":"NCT05383170 - Catalyst","lead_sponsor":"Cytovation AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CY-101"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 09/23/2024","primary_completion_date":" 09/23/2024","study_txt":" Completion: 09/23/2024","study_completion_date":" 09/23/2024","last_update_posted":"2024-09-27"},{"id":"e975dc1c-7e02-40e7-855c-de3886574f07","acronym":"CICILIA","url":"https://clinicaltrials.gov/study/NCT04260529","created_at":"2021-10-14T21:53:05.598Z","updated_at":"2025-02-25T16:09:57.834Z","phase":"Phase 1/2","brief_title":"CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations","source_id_and_acronym":"NCT04260529 - CICILIA","lead_sponsor":"Cytovation AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CY-101"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2020","start_date":" 04/30/2020","primary_txt":" Primary completion: 07/05/2024","primary_completion_date":" 07/05/2024","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-07-24"}]